Arca
Skip to content
Tools
Tools

MSLN: Mesothelin

Membrane-anchored forms may play a role in cellular adhesion.

  • Drugs that act on it: 5
  • Approved: 0
  • In phases 1 to 3: 5
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on MSLN, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Antibody-drug conjugate 1
  • Other 3

Approved0

    Phase 30

      Phase 23

      • Anetumab ravtansine
      • Amatuximab
      • LMB-100

      Phase 12

      • RG-7600
      • SS1(DSFV)-PE38

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Morphotek120%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 5 act as: Mesothelin binding agent; the rest name their own mechanism.
      Anetumab ravtansinePhase 2BayerAntibody-drug conjugateBinding agent3
      AmatuximabPhase 2MorphotekAntibodyInhibitorMesothelin inhibitor0
      LMB-100Phase 2RocheOtherBinding agent0
      RG-7600Phase 1—OtherBinding agent0
      SS1(DSFV)-PE38Phase 1Insys TherapeuticsOtherBinding agent0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.
      Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic CancerAnetumab ravtansinePhase 1Active, not recruitingNational Cancer Institute (NCI)Jan 25, 2019
      Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerAnetumab ravtansinePhase 2Active, not recruitingNational Cancer Institute (NCI)Jul 16, 2018
      Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural MesotheliomaAnetumab ravtansinePhase 1 / Phase 2Active, not recruitingNational Cancer Institute (NCI)Apr 24, 2017

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Neoplasm0.14
      • Pancreatic neoplasm0.13
      • Ovarian carcinoma0.12
      • Non-small cell lung carcinoma0.12
      • Lung adenocarcinoma0.11
      • Triple-negative breast carcinoma0.11
      • Familial pancreatic carcinoma0.11

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712878, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q13421, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.